

전자담배와 호흡기질환

경희의료원

호흡기내과

최혜숙


강의 순서

- 전자담배
- 전자담배와 금연
- 전자담배의 호흡기영향




구분	일반궐련담배	궐련형 전자담배	(액상형) 전자담배
흡입방식	직접연소 를 통해 배출물 흡입 Burn	전자기기를 통해 전용스틱을 고열로 가열 하여 배출물 흡입 Heat-not-burn	니코틴이 함유되거나 혹은 특정한 향을 갖춘 액체를 가 열 하여 배출물 흡입
가열온도	650~850 °C	250~350 °C	250~350 °C

액상형 전자담배




꺾련형 전자담배



2015 흡연실태 수시조사 (질병관리본부)

전자담배사용 주된 이유



강의 순서

➤ 전자담배

➤ **전자담배와 금연**

➤ 전자담배의 호흡기영향

전자담배는 금연에 도움이 될까?



Cochrane
Library


Cochrane Database of Systematic Reviews

Electronic cigarettes for smoking cessation (Review)

Hartmann-Boyce J, McRobbie H, Bullen C, Begh R, Stead LF, Hajek P

Smoking cessation

Nicotine EC vs. placebo EC





HHS Public Access

Author manuscript

Addict Behav. Author manuscript; available in PMC 2019 January 01.

Published in final edited form as:

Addict Behav. 2018 January ; 76: 129–134. doi:10.1016/j.addbeh.2017.08.002.


Prevalence of population smoking cessation by electronic cigarette use status in a national sample of recent smokers

Daniel P. Giovenco, PhD, MPH¹ and Cristine D. Delnevo, PhD, MPH²

¹Columbia University Mailman School of Public Health, Department of Sociomedical Sciences, 722 W. 168th St., New York, NY, USA 10032

²Rutgers School of Public Health, Center for Tobacco Studies, 683 Hoes Ln West, Piscataway, NJ, USA 08854

Prevalence of quit



ORIGINAL ARTICLE

A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy

Peter Hajek, Ph.D., Anna Phillips-Waller, B.Sc., Dunja Przulj, Ph.D.,
Francesca Pesola, Ph.D., Katie Myers Smith, D.Psych., Natalie Bisal, M.Sc.,
Jinshuo Li, M.Phil., Steve Parrott, M.Sc., Peter Sasieni, Ph.D.,
Lynne Dawkins, Ph.D., Louise Ross, Maciej Goniewicz, Ph.D., Pharm.D.,
Qi Wu, M.Sc., and Hayden J. McRobbie, Ph.D.

Table 2. Abstinence Rates at Different Time Points and Smoking Reduction at 52 Weeks.*

Outcome	E-Cigarettes (N = 438)	Nicotine Replacement (N = 446)	Primary Analysis: Relative Risk (95% CI)†	Sensitivity Analysis: Adjusted Relative Risk (95% CI)
Primary outcome: abstinence at 52 wk — no. (%)	79 (18.0)	44 (9.9)	1.83 (1.30–2.58)	1.75 (1.24–2.46)‡
Secondary outcomes				
Abstinence between wk 26 and wk 52 — no. (%)	93 (21.2)	53 (11.9)	1.79 (1.32–2.44)	1.82 (1.34–2.47)§
Abstinence at 4 wk after target quit date — no. (%)	192 (43.8)	134 (30.0)	1.45 (1.22–1.74)	1.43 (1.20–1.71)¶
Abstinence at 26 wk after target quit date — no. (%)	155 (35.4)	112 (25.1)	1.40 (1.14–1.72)	1.36 (1.15–1.67)‡
Carbon monoxide–validated reduction in smoking of ≥50% in participants without abstinence between wk 26 and wk 52 — no./total no. (%)	44/345 (12.8)	29/393 (7.4)	1.75 (1.12–2.72)	1.73 (1.11–2.69)¶

강의 순서


➤ 전자담배

➤ 전자담배와 금연


➤ **전자담배의 호흡기영향**

**The Role of Nicotine in the Effects of Maternal Smoking during
Pregnancy on Lung Development and Childhood Respiratory Disease**
Implications for Dangers of E-Cigarettes


$\alpha 7$ nicotinic acetylcholine receptors (nAChRs)
control





Nicotine-exposed




collagen
control




Nicotine-exposed



control
Masson trichrome-stained



Nicotine-exposed



Trichrome-stained human lung infant death syndrome whose mother smoked during pregnancy
Perivascular blue collagen fibers

(액상형) 전자담배 유해성

구분	성분명	액상 중 함량(μg/g)	기체상 중	
			함량(μg/g)	함량(μg/cig')
	니코틴	7000 - 13500	6500 - 12400	330 - 670
카르보닐류	포름알데히드	NQ - 26.1	NQ - 85.7	NQ - 4.2
	아세트알데히드	NQ - 14.7	NQ - 49.1	NQ - 2.4
	아세톤	NQ - 8.3	NQ - 30.9	NQ - 1.5
	아크롤레인	NQ	NQ	NQ
	프로피오알데히드	NQ - 8.3	NQ - 144.9	NQ - 7.1
	크로톤알데히드	NQ - 55.3	NQ	NQ

꺄련담배와 유사

Propylene glycol and glycerol


전자담배 액상 및 기체상 카르보닐류 분석결과 (µg/g)

구분	제품	액상 카르보닐류 검출량(µg/g)						기체상 카르보닐류 검출량(µg/g)					
		FA'	AA'	AC'	AL'	PA'	CA'	FA	AA	AC	AL	PA	CA
전체	범위	NQ~ 26.1	NQ~ 14.7	NQ~ 8.3	NQ	NQ~ 8.3	NQ~ 55.3	NQ~ 85.7	NQ ~ 49.1	NQ~ 30.9	NQ	NQ~ 144.9	NQ

FA: 포름알데히드, AA: 아세트알데히드, AC: 아세톤, AL: 아크롤레인,
PA: 프로피온알데히드, CA: 크로톤알데히드

가열되는 코일: 크롬과 납, 니켈

'Real-world' compensatory behaviour with low nicotine concentration e-liquid: subjective effects and nicotine, acrolein and formaldehyde exposure



* concentrationX10


** p <0.05 compare to all groups

	Chemical	Detected Concentration Range	Biological System Affected
	Nicotine	ND to 36.6 mg/mL ^{10,62,63}	Lung tumor promoter ⁶⁷ Addiction ⁶⁷ Gastrointestinal carcinogen ⁶⁷ Raises blood pressure and heart rate ⁶⁸ Reduce brain development in adolescents ³⁷
	Cotinine	ND*	Reduce fertility and reproduction ⁶⁹
Aldehydes	Acetaldehyde	0.11 to 2.94 µg/15 puffs ^{53,64,65}	Carcinogen ⁷⁰ Aggravation of alcohol-induced liver damage ⁷¹
	Acrolein	0.044 to 6.74 µg/15 puffs ^{53,64,65}	Ocular irritation ⁷² Respiratory irritation ⁷² Gastrointestinal irritation ⁷²
	Formaldehyde	0.2 to 27.1 µg/15 puffs ^{53,64,65}	Carcinogen ⁶⁸ Bronchitis, pneumonia, and increase asthma risk in children ^{73,74} Ocular, nasal, and throat irritant ⁷⁴
	o-Methyl benzaldehyde	ND to 7.1 µg/15 puffs ⁷	Unknown
	Acetone	ND to 91.2 ⁷	Gastric distress ⁷⁵ Weakness of extremities and headache ⁷⁵ Ocular irritation ⁷⁵
Volatile organic compounds	Propylene glycol	0 to 82.875 mg/15 puffs ⁷	Throat and airways irritation. ⁷⁶ Carcinogen ⁶⁸ Gastric distress ⁶⁸ Increase asthma risk in children ⁶⁸ Ocular irritation ⁶⁸
	Glycerin	75 to 225 µg/15 puffs ⁵⁷	Lipoid pneumonia ⁷⁷ Ocular, dermal, and pulmonary irritant ⁷⁸


Potential Effects of e-Cigarettes on Biological Systems

System	Effects of e-Cigarettes
Pulmonary system	Upper and lower respiratory tract irritation ^{9,26,27} Bronchitis, cough, and emphysema ^{9,26,27}

Lung injury, lung cancer.....



Prevalence rates of asthma in high school students of south Korea





RR in multivariate model for Chronic Pulmonary Disorder

Variable	AOR	CI	p	Hawaii BRFSS, Telephone survey
E-cigarette use	2.58	1.36 - 4.89	.004	
Cigarette smoking	2.98	2.34 - 3.78	< .0001	
Cigarette smoking	2.98	2.34 - 3.78	< .0001	
E-cig X smoking	0.51	0.26 - 1.00	.05	
Pairwise comparisons				
Dual vs. none	3.92	2.82 - 5.44	< .0001	
Smok vs. none	2.98	2.34 - 3.78	< .0001	
E-cig vs. none	2.58	1.36 - 4.89	.004	
Dual vs. e-cig	1.52	0.81 - 2.87	.20	
Smok vs. e-cig	1.16	0.62 - 2.17	.65	
Dual vs. smok	1.32	0.98 - 1.77	.07	
Gender (male)	0.71	0.58 - 0.88	.001	
Education	0.88	0.79 - 0.98	.03	
Financial stress	1.19	1.08 - 1.31	.0006	
Overweight status	1.11	0.96 - 1.27	.15	
Secondhand smoke	1.37	1.15 - 1.63	.0003	
Native Hawaiian ^A	1.11	0.84 - 1.48	.47	
Filipino	0.82	0.58 - 1.17	.27	
Japanese	0.62	0.46 - 0.83	.001	
Chinese	0.58	0.30 - 1.12	.11	
Pacific Islander	1.16	0.56 - 2.40	.69	
Other Asian	0.56	0.21 - 1.51	.25	

E-Cigarette Use Causes a Unique Innate Immune Response in the Lung, Involving Increased Neutrophilic Activation and Altered Mucin Secretion

Boris Reidel^{1,2}, Giorgia Radicioni^{1,2}, Phillip W. Clapp³, Amina A. Ford^{1,2}, Sabri Abdelwahab^{1,2}, Meghan E. Rebuli³, Prashamsha Haridass^{1,2}, Neil E. Alexis³, Ilona Jaspers³, and Mehmet Kesimer^{1,2}





¹Marsico Lung Institute, ²Department of Pathology and Laboratory Medicine, and ³Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

A**B**

response in the
Altered



ab^{1,2}, Meghan E. Rebuli³,

iatrics, The University of North


C**D****E****F**

Exposure in mice induces independent manner


Baumlin,³ Michael Campos,³
Gins,⁵ Edward Eden,⁵
,²




Genes differentially expressed in human bronchial epithelial cells exposed to traditional tobacco cigarette (TCIG) smoke or electronic cigarette (ECIG) aerosol.




EGR reduced expression



5 target genes in cigarette smokers



18 target genes in e-cigarette users






CrossMark

Electronic cigarettes: a task force report from the European Respiratory Society

Experiments in cell cultures and animal studies show that ECIGs can have multiple negative effects.

The long-term effects of ECIG use are unknown, and there is therefore no evidence that ECIGs are safer than tobacco in the long term.

Based on current knowledge, negative health effects cannot be ruled out.



수시 3호, 2019. 9. 20.

“미국 내 전자담배(액상형) 관련 중증 폐질환 발생에 대한 정부 대책 안내”

□ 미국 발생 현황 및 관리

○ 미국 질병통제센터(CDC)는 2019년 9월 24일 기준으로 미국 전역에서 액상형

증례

Pulmonary illness: EC-nicotine containing liquids

18-year-old woman → live

Hypersensitivity Pneumonitis and Acute Respiratory Distress Syndrome From E-Cigarette Use

Casey G. Sommerfeld, MD, Daniel J. Weiner, MD, Andrew Nowalk, MD, PhD, Allyson Larkin, MD

Pediatrics 2018; 141(6): e20163927

CASE REPORT

40-year-old female → live

WILEY

Organizing pneumonia related to electronic cigarette use: A case report and review of literature

Clin Respir J 2018; 12:1295



18-year-old female → live

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Respiratory Medicine Case Reports

ELSEVIER

journal homepage: www.elsevier.com/locate/rmcr

Case report

Acute eosinophilic pneumonia following electronic cigarette use

Respir Med Case Rep 2019; 27: 100825.

TABLE 1 Case reports of pulmonary toxicity caused by e cigarettes

Age/sex	Preexisting medical conditions	Smoking history	Duration of e cigarette use before diagnosis	Presentation/sign and symptoms	Diagnosis	Treatment/outcome
42/F ¹¹	Asthma, Rheumatoid arthritis, Fibromyalgia, Schizoaffective disorder, Hypertension	Not specified	7 months	Dyspnoea, cough, fever	Exogenous lipoid pneumonia	Recovery with abstinence from e cigarette
20/M ¹⁴	None	Not specified	3 days	Dyspnoea and cough	Acute eosinophilic pneumonia	Recovery with abstinence from e cigarette and systemic steroids
43/M ¹³	Lung adenocarcinoma with isolated brain metastasis	Smoker, 45 pack year	4 weeks	Dyspnoea and cough	Subacute bronchial toxicity	Recovery with abstinence from e cigarette
31/F ¹²	Not specified	Smoker, unspecified	3 months	Dyspnoea and cough	Exogenous lipoid pneumonia	Recovery with abstinence from e cigarette and systemic steroids
43/M ¹⁵	Hypertension	Smoker, unspecified	3 days	Dyspnoea and pleuritic chest pain	Pneumonia and bilateral pleural effusions	Recovery with abstinence from e cigarette
60/M ¹⁶	Not specified	Smoker, unspecified	Not specified	Weakness and cough	Suspected acute hypersensitivity pneumonitis	Recovery with abstinence from e cigarette
33/M ¹⁷	Mixed Germ cell tumour with multiple pulmonary metastasis	Smoker, 10 pack years	3 months	Dyspnoea	Respiratory bronchiolitis interstitial lung disease	Recovery with abstinence from e cigarette
27/M ¹⁸	None	Smoker, unspecified	7 months	Dyspnoea, cough, fever and hemoptysis	Bronchiolitis obliterans organizing pneumonia	Recovery with abstinence from e cigarette and systemic steroids
70/M ¹⁹	Lung cancer with left upper lobectomy and COPD	Not specified	4 weeks	Dyspnoea and cough	Diffuse alveolar damage	Death

Pulmonary illness: EC-cannabis (THC, CBD)

What Is Dabbing? And Should You Do It?

The First Time I Tried It, I Couldn't Believe How High I Got
by Lester Black

ds

Case report 18-year-old female

Lung injury from inhaling butane hash oil mimics pneumonia

Respir Med Case Rep 2019;26: 171-3.

methacrolein and benzene



STEP 1: USE A BLOWTORCH TO HEAT UP THE NAIL



STEP 2: USE A DABBER (OR SCALPEL) TO PICK UP A CHUNK OF CONCENTRATE



STEP 3: DROP THE CONCENTRATE ONTO THE HOT NAIL AND INHALE




STEP 4: FIND YOURSELF THE NEAREST COUCH AND STAY THERE

"Tree-in-Bloom": Severe Acute Lung Injury Induced by Vaping Cannabis Oil

54-year-old man

[Ann Am Thorac Soc.](#) 2017 Mar;14(3):468-470.



Morbidity and Mortality Weekly Report (*MMWR*)

CDC



Severe Pulmonary Disease Associated with Electronic–Cigarette–Product Use — Interim Guidance

Weekly / September 13, 2019 / 68(36);787–790

On September 6, 2019, this report was posted online as an MMWR Early Release.

Please note: An erratum has been published for this report. To view the erratum, please click [here](#).

Joshua G. Schier, MD¹; Jonathan G. Meiman, MD²; Jennifer Layden, MD³; Christina A. Mikosz, MD¹; Brenna VanFrank, MD⁴; Brian A King, PhD⁴; Phillip P. Salvatore, PhD^{1,5}; David N. Weissman, MD⁶; Jerry Thomas, MD⁷; Paul C. Melstrom, PhD⁴; Grant T. Baldwin, PhD¹; Erin M. Parker, PhD¹; Elizabeth A. Courtney-Long, MSPH⁴; Vikram P. Krishnasamy, MD¹; Cassandra M. Pickens, PhD¹; Mary E. Evans, MD¹; Sharon V. Tsay, MD¹; Krista M. Powell, MD¹; Emily A. Kiernan, MD⁸; Kristy L. Marynak, MPP⁴; Jennifer Adjemian, PhD⁹; Kelly Holton¹; Brian S. Armour, PhD⁴; Lucinda J. England, MD¹⁰; Peter A. Briss, MD⁴; Debra Houry, MD¹; Karen A. Hacker, MD⁴; Sarah Reagan-Steiner, MD¹¹; Sherif Zaki, MD¹¹; Dana Meaney-Delman, MD¹¹; CDC 2019 Lung Injury Response Group ([View author affiliations](#))

[View suggested citation](#)

Summary

What is already known about this topic?

Twenty-five states have reported more than 200 possible cases of severe pulmonary disease associated with the use of electronic cigarettes (e-cigarettes).

What is added by this report?

Based on available information, the disease is likely caused by an unknown chemical exposure; no single product or substance is conclusively linked to the disease.

Article Metrics

Altmetric:



Citations: 0

ORIGINAL ARTICLE

Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin — Preliminary Report

Jennifer E. Layden, M.D., Ph.D., Isaac Ghinai, M.B., B.S., Ian Pray, Ph.D.,
Anne Kimball, M.D., Mark Layer, M.D., Mark Tenforde, M.D., Ph.D.,
Livia Navon, M.S., Brooke Hoots, Ph.D., Phillip P. Salvatore, Ph.D.,
Megan Elderbrook, M.P.H., Thomas Haupt, M.S., Jeffrey Kanne, M.D.,
Megan T. Patel, M.P.H., Lori Saathoff-Huber, M.P.H.,
Brian A. King, Ph.D., M.P.H., Josh G. Schier, M.D.,
Christina A. Mikosz, M.D., M.P.H., and Jonathan Meiman, M.D.





Table 2. Demographic Characteristics, Symptoms, Evaluation, and Clinical Course of 53 Case Patients.^a

Characteristic	Values
Median age (range) — yr	19 (16–53)
Male sex — no./total no. (%)	44/53 (83)
Race or ethnic group — no./total no. (%) [†]	
White	37/45 (82)





Figure 3. Emergency Department (ED) Visits for Severe Unexplained Respiratory Illness among Patients 14 to 30 Years of Age, According to Sex, in Illinois Counties in 2018 and 2019.

Receipt of noninvasive positive-pressure ventilation — no./total no. (%)	19/53 (36)
Intubation and mechanical ventilation — no./total no. (%)	17/53 (32)
Admission to intensive care unit — no./total no. (%)	31/53 (58)
Death — no./total no. (%)	1/53 (2)

전자담배 사용실태 (90일 이내)



- Tetrahydrocannabinol (THC): 대마초주성분
- Cannabidiol (CBD): 대마초성분
- Butane hash oil (dabs): 대마기름





Morbidity and Mortality Weekly Report (*MMWR*)

CDC



Characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping — United States, 2019

Weekly / October 4, 2019 / 68(39);860–864

On September 27, 2019, this report was posted online as an MMWR Early Release.

Cria G. Perrine, PhD¹; Cassandra M. Pickens, PhD²; Tegan K. Boehmer, PhD³; Brian A. King, PhD¹; Christopher M. Jones, DrPH²; Carla L. DeSisto, PhD^{1,4}; Lindsey M. Duca, PhD^{1,4}; Akaki Lekiachvili, MD¹; Brandon Kenemer, MPH¹; Mays Shamout, MD^{1,4}; Michael G. Landen, MD⁵; Ruth Lynfield, MD⁶; Isaac Ghinai, MBBS^{4,7}; Amy Heinzerling, MD^{4,8}; Nathaniel Lewis, PhD^{4,9}; Ian W. Pray, PhD^{4,10}; Lauren J. Tanz, ScD^{4,11}; Anita Patel, PharmD¹²; Peter A. Briss, MD¹; Lung Injury Response Epidemiology/Surveillance Group ([View author affiliations](#))

[View suggested citation](#)

Summary

What is already known about this topic?

Lung injury associated with e-cigarette use, or vaping, has recently been reported in most states. CDC, the Food and Drug Administration, and others are investigating this outbreak.

What is added by this report?

Among 805 cases reported as of September 24, 2019, 69% were in males; 62% of patients were aged 18–34 years. Among patients with data on substances used in e-cigarettes, or vaping products, tetrahydrocannabinol (THC)-containing product use was reported by 76.9% (36.0% reported exclusive THC-product use); 56.8% reported nicotine-containing product use (16.0% reported exclusive nicotine-product use).

What are the implications for public health practice?

Article Metrics

Altmetric:



Citations: 0

Views: 20,056

Views equals page views plus PDF downloads

Characteristic	No. (%)
----------------	---------

Demographic (n = 771)*

Sex

Male	531 (68.9)
------	------------

Female	234 (30.4)
--------	------------

Missing	6 (0.8)
---------	---------

Age group (yrs)

<18	125 (16.2)
-----	------------

18–24	293 (38.0)
-------	------------

25–34	184 (23.9)
-------	------------

35–44	93 (12.1)
-------	-----------

≥45	42 (5.5)
-----	----------

Missing	34 (4.4)
---------	----------

Substances used in e-cigarette, or vaping, products (n = 514)[†]

THC-containing products

Yes	395 (76.9)
No	96 (18.7)
Unknown/Missing	23 (4.5)

Nicotine-containing products

Yes	292 (56.8)
No	173 (33.7)
Unknown/Missing	49 (9.5)

Cannabidiol (CBD)


Yes	89 (17.3)
No	265 (51.6)
Unknown/Missing	160 (31.1)

Synthetic cannabinoids

Yes	4 (0.8)
No	289 (56.2)
Unknown/Missing	221 (43.0)

Flavored e-liquids[§]

Yes	103 (19.9)
-----	------------



Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping

[Español \(Spanish\)](#)

Table of Contents

[For the Public](#)

[For Healthcare](#)

[For State and](#)

[Resources](#)

- ◆ October 8, 2019, 1,299* lung injury cases
- ◆ 26 deaths
- ◆ 70% male
- ◆ 80% <35 years old

Posted October 10, 2019 at 1:00pm ET

CDC, the U.S. Food and Drug Administration (FDA), state and local health departments, and other clinical and public health partners are investigating a multistate outbreak of lung injury associated with use of e-cigarette, or vaping, products.

On This Page

[What we know](#)

[What we don't know](#)

[What CDC recommends](#)

[Key Facts about E-Cigarette Us](#)

전자담배 관련 중증 폐질환 사례정의

<p>확진자 (Confirmed)</p>	<ul style="list-style-type: none">· 질환 최초 발생 전 90일 동안 전자담배를 사용하고,· 흉부 이미지 영상에서 이상 소견이 있고,· 임상이나 분자적 진단검사(viral panel, PCR) 결과 감염성 폐질환 소견도 없으며,· 심장질환, 류머티스, 종양 등의 병력이 없는 경우
<p>추정환자 (Probable)</p>	<ul style="list-style-type: none">· 질환 최초 발생 전 90일 동안 전자담배를 사용하고,· 흉부 이미지 영상에서 이상 소견이 있고,· 진단검사 결과 감염 소견이 있으나, 임상소견 상 감염이 단독원인이 아니라고 판단되며,· 심장질환, 류머티스, 종양 등의 병력이 없는 경우

본임 3 전자담배(액상형) 관련 중증 폐질환 의심환자 발생보고서

신고의도기관명	000 의도기관	연락처	조사일	년 월 일
작성일자				

환자 인적사항	성명 :	성별 : <input type="checkbox"/> 남 <input type="checkbox"/> 여	연락처	핸드폰 :
	생년월일		거주지주소	의료기관 전화 :
조사항목	전자담배사용력 (최근 90일 내 전자담배 사용력)	사용 제품명 (많이 사용한 순서대로)	사용 기간 (단년도)	사용 빈도
		예시) A	년 월 ~ 년 월/ 년 월 ~ 년 월	(7회/ 1주일)
		예시) B	년 월 ~ 년 월/ 년 월 ~ 년 월	(1회/ 1주일)
		예시) C	년 월 ~ 년 월/ 년 월 ~ 년 월	(1회/ 1주일)
사례 정의	<input type="checkbox"/> 확진자 (Confirmed)		<input type="checkbox"/> 추정환자 (Probable)	
	<ul style="list-style-type: none"> · 질환 최초 발생 전 90일 동안 전자담배를 사용하고, · 흉부 이미지 영상에서 이상 소견이 있고, · 임상이나 진단검사 결과 어떤 감염성 폐질환 소견도 없으며, · 심장질환, 류머티스, 종양 등의 병력이 없는 경우 		<ul style="list-style-type: none"> · 질환 최초 발생 전 90일 동안 전자담배를 사용하고, · 흉부 이미지 영상에서 이상 소견이 있고, · 진단검사 결과 감염 소견 있으나, 임상소견 상 감염이 단독원인이 아니라고 판단되며, · 심장질환, 류머티스, 종양 등의 병력이 없는 경우 	
발병일	년 월 일			
주증상	<input type="checkbox"/> 발열(°C) <input type="checkbox"/> 기침 <input type="checkbox"/> 피로감 <input type="checkbox"/> 숨가쁨 <input type="checkbox"/> 가슴통증 <input type="checkbox"/> 구토 <input type="checkbox"/> 설사 <input type="checkbox"/> 기타()			
참고사항	<p>○(발병 보고) 중증 폐질환자 내원 시, 역학적 연관성(발병 전 90일 내 액상형 전자담배 사용)을 확인하고 진단을 위한 검사를 시행하여 사례 정의에 부합하는 경우는 자체, 없이 질병관리본부 건강영양조사과로 발생보고서를 작성해서 매일 또는 팩스로 제출하여 주시기 바랍니다</p> <p>☞ 보고방법 : 메일(kims0906@korea.kr) 또는 팩스 (043-719-7527) 문의처 : 043-719-7461, 7463</p> <p>○(권고사항) 병원 내원자 중 액상형 전자담배 사용자에는 최근 90일 이내에 폐질환 증상유무에 대해 조사하여 과거력이 확인된 경우, 액상형 전자담배의 사용을 중단할 것을 권고하여 주시기 바랍니다</p> <p>○(사례조사 시 협조요청) 향후 사례 조사가 진행될 경우, 추가 협조를 부탁드립니다</p>			


액상형 전자담배 THC, CBD vs nicotine ?

VS

궐련형 전자담배

iQOS: evidence of pyrolysis and release of a toxicant from plastic

Barbara Davis, Monique Williams, Prue Talbot



맺음말

- 전자담배

1. 금연에 도움을 주는가?

2. 액상형 전자담배의 해로움

니코틴, 마리화나, 가향성분, 액상성분

3. 궤련형전자담배의 해로움

4. 앞으로 해야할 일